KURA - Kura Oncology

-

$undefined

N/A

(N/A)

Kura Oncology NasdaqGS:KURA Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.

Location: 12730 High Bluff Drive, San Diego, CA, 92130, United States | Website: https://kuraoncology.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-146.2M

Cash

658.2M

Avg Qtr Burn

N/A

Short % of Float

12.40%

Insider Ownership

1.09%

Institutional Own.

94.32%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Ziftomenib + Induction Chemotherapy (7+3) Details
Blood cancer, Acute myeloid leukemia, Cancer

Phase 3

Initiation

Ziftomenib + venetoclax + azacitidine Details
Blood cancer, Acute myeloid leukemia, Cancer

Phase 3

Initiation

Tipifarnib + alpelisib Details
Head and neck cancer, Head and neck squamous cell carcinoma, Cancer

Phase 1/2

Data readout

Ziftomenib Details
Acute myeloid leukemia, Blood cancer, Cancer

Phase 1/2

Data readout

Ziftomenib + venetoclax/azacitidine Details
Blood cancer, Acute myeloid leukemia, Cancer

Phase 1b

Data readout

Phase 1b

Data readout

Ziftomenib + gilteritinib Details
Acute myeloid leukemia, Blood cancer, Cancer

Phase 1

Data readout

Ziftomenib + imatinib Details
Gastrointestinal stromal tumors

Phase 1

Data readout

KO-2806 +cabozantinib Details
Advanced Renal Cell Carcinoma

Phase 1

Data readout

KO-2806 Monotherapy Details
Renal Cell Carcinoma

Phase 1

Data readout

KO-2806 Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Phase 1

Data readout

KO-2806 + cabozantinib Details
Solid tumor/s, Renal cell carcinoma, Cancer

Phase 1

Data readout

Tipifarnib Details
Cancer, T-cell lymphoma, Lymphoma

Failed

Discontinued

Tipifarnib Details
Head and neck cancer, Cancer, Head and neck squamous cell carcinoma

Failed

Discontinued